Stablepharma’s Fridge-Free Vaccine that Eliminates the Need for Cold Chain entering First-in-Human UK Clinical Trial. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Stablepharma to begin a Phase I clinical trial with SPVX02, an adult booster vaccine aimed at preventing tetanus and diphtheria (Td) infections. This approval marks a major […]
Read More
Stablepharma has announced the appointment of Dr. Kenny Simmen as its Chief Business Officer, effective March 1, 2025. Following a year of service on the company’s Advisory Board, Dr. Simmen will now lead Stablepharma’s business development efforts, including partnering and licensing activities, as part of the company’s ambitious growth strategy. Dr Simmen has 30 years […]
Read More
London, 19th February 2025 – UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s rigorous criteria for excellence, impact, and risk management. Stablepharma is among 71 companies from 16 countries across Europe selected […]
Read More
Bath, United Kingdom, December 4th, 2024 – Stablepharma Ltd today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce Biotech and Fierce Pharma in the Biotech Innovation category. The awards program highlights and showcases outstanding innovation that is driving improvements and transforming the industry. “The Innovation Awards winners showcase the organizations that have […]
Read More click here to read full article
Read More
Innovation takes centre stage at Pharma Industry Awards UK 2024 Brought to you by Clinical innovation and manufacturing excellence share the spotlight at this year’s awards December 11 2024, 12:01am Ipsen has been named Pharma Industry Company of the Year at the second annual Pharma Industry Awards UK, recognising their outstanding achievement in potency robustness. […]
Read More
Dr. Steven Chatfield appointed as Non-Executive Chairman of Stablepharma, following an extensive career in vaccine R&D and Covid19 Pandemic. Dr. Chatfield, who currently serves on Stablepharma’s Advisory Board, is taking on the role of Non-Executive Chairman of the company in November. He has been instrumental in advising and advancing the launch of SPVX02, a fridge-free […]
Read More
Dr. Bruce Roser, MB BS, PhD, Chairman and co-founder of Stablepharma, is retiring, leaving behind a remarkable legacy in the field of fridge-free vaccines and pharmaceuticals. Through his tireless efforts to validate the science behind this ground-breaking technology, which culminated in Stablepharma’s technology platform StablevaX™, Dr. Roser has made a significant contribution to the future […]
Read More
Stablepharma is delighted to announce that we have been selected as to be part of Innovate UK’s prestigious Scaleup Programme, in recognition of our potential to grow exponentially and scale globally. The Scaleup Programme is provided by Innovate UK Business Growth, the innovation agency’s national business growth and scaling service, which supports businesses to grow […]
Read More
Stablepharma Ltd in collaboration with their leading global CDMO partner have achieved a significant milestone in the GMP manufacture of their lead candidate, fridge-free Tetanus Diphtheria vaccine (SPVX02), based on StablevaX™ technology. Stablepharma have reported the successful manufacture and analytical testing of over 10,000 vials (doses) of SPVX02 under GMP conditions, in Monza, Italy and […]
Read More